ATE556712T1 - A2a antagonisten zur behandlung von motorischen störungen - Google Patents

A2a antagonisten zur behandlung von motorischen störungen

Info

Publication number
ATE556712T1
ATE556712T1 AT10005600T AT10005600T ATE556712T1 AT E556712 T1 ATE556712 T1 AT E556712T1 AT 10005600 T AT10005600 T AT 10005600T AT 10005600 T AT10005600 T AT 10005600T AT E556712 T1 ATE556712 T1 AT E556712T1
Authority
AT
Austria
Prior art keywords
antagonists
treatment
hydrogen atom
motor disorders
substituted
Prior art date
Application number
AT10005600T
Other languages
English (en)
Inventor
Takako Kadowaki
Minoru Kobayashi
Shizuo Shiozaki
Naoki Seno
Original Assignee
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kirin Co Ltd
Application granted granted Critical
Publication of ATE556712T1 publication Critical patent/ATE556712T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
AT10005600T 2005-06-07 2006-06-07 A2a antagonisten zur behandlung von motorischen störungen ATE556712T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2005166981 2005-06-07

Publications (1)

Publication Number Publication Date
ATE556712T1 true ATE556712T1 (de) 2012-05-15

Family

ID=37498474

Family Applications (1)

Application Number Title Priority Date Filing Date
AT10005600T ATE556712T1 (de) 2005-06-07 2006-06-07 A2a antagonisten zur behandlung von motorischen störungen

Country Status (6)

Country Link
US (1) US7851478B2 (de)
EP (2) EP1902716A4 (de)
JP (3) JPWO2006132275A1 (de)
AT (1) ATE556712T1 (de)
ES (1) ES2385702T3 (de)
WO (1) WO2006132275A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7994190B2 (en) 2006-11-01 2011-08-09 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
AU2010207004A1 (en) * 2009-01-20 2011-07-28 Merck Sharp & Dohme Corp. Methods of alleviating or treating signs and/or symptoms associated with moderate to severe Parkinson's disease
JP5765239B2 (ja) 2009-03-13 2015-08-19 アドヴィナス・セラピューティックス・リミテッド 置換縮合ピリミジン化合物
TWI548411B (zh) * 2009-04-28 2016-09-11 Kyowa Hakko Kirin Co Ltd Exercise disorder treatment
EP2499142B1 (de) 2009-11-09 2016-09-21 Advinus Therapeutics Limited Substituierte kondensierte pyrimidinverbindungen, ihre herstellung und ihre verwendung
ES2579949T3 (es) 2010-02-05 2016-08-17 Heptares Therapeutics Limited Derivados de 1,2,4-triazin-4-amina
WO2012066330A1 (en) 2010-11-17 2012-05-24 Heptares Therapeutics Limited Compounds useful as a2a receptor inhibitors
JP6308346B2 (ja) * 2013-05-31 2018-04-11 三菱自動車工業株式会社 車両の制御装置
JP6381883B2 (ja) * 2013-10-04 2018-08-29 国立大学法人千葉大学 不随意運動の予防及び／又は治療組成物
US20200316077A1 (en) 2017-12-19 2020-10-08 Impetis Biosciences Ltd. Pharmaceutical composition for the treatment of cancer
AU2019205661B2 (en) * 2018-01-04 2022-06-30 Impetis Biosciences Ltd. Tricyclic compounds, compositions and medicinal applications thereof
WO2019168847A1 (en) 2018-02-27 2019-09-06 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
EP3810610A1 (de) 2018-05-18 2021-04-28 Incyte Corporation Kondensierte pyrimidinderivate als a2a/a2b-inhibitoren
KR20210049090A (ko) 2018-07-05 2021-05-04 인사이트 코포레이션 A2a/a2b 억제제로서 융합된 피라진 유도체
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
CN113692306B (zh) * 2019-04-03 2024-06-21 泰拉强石株式会社 基于胸腺嘧啶核酸碱基的三唑并嘧啶类及其制造方法
WO2022029063A1 (en) 2020-08-04 2022-02-10 Bayer Aktiengesellschaft Pyrido[1,2,4]triazolo[1,5-c]pyrimidin-5-amines

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2311806A3 (de) * 1996-01-29 2011-08-10 The United States of America, Represented by the Secretary, Department of Health and Human Services Dihydropyridin-, Pyridin-, Benzopyranon- und Triazolchinazolinderivate, ihre Herstellung und Verwendung als Adenosinrezeptorantagonisten
ATE257156T1 (de) 1997-03-24 2004-01-15 Kyowa Hakko Kogyo Kk (1,2,4)triazolo(1,5-c)pyrimidin-derivate
WO1999043678A1 (fr) 1998-02-24 1999-09-02 Kyowa Hakko Kogyo Co., Ltd. Medicaments et prophylaxie contre la maladie de parkinson
ATE286900T1 (de) * 1998-09-22 2005-01-15 Kyowa Hakko Kogyo Kk (1,2,4)triazolo(1,5-c)pyrimidin-derivate
EP1177797A1 (de) 1999-05-12 2002-02-06 Fujisawa Pharmaceutical Co., Ltd. Neue verwendung
US20040152659A1 (en) * 1999-05-12 2004-08-05 Fujisawa Pharmaceutical Co. Ltd. Method for the treatment of parkinson's disease comprising administering an A1A2a receptor dual antagonist
JP2001302648A (ja) * 2000-04-28 2001-10-31 Kyowa Hakko Kogyo Co Ltd ピペラジン誘導体の製造法
SK287748B6 (sk) * 2000-05-26 2011-08-04 Schering Corporation Substituované 5-amino-pyrazolo[4,3-e]-1,2,4-triazolo[1,5- c]pyrimidíny, spôsob ich výroby, farmaceutický prostriedok s ich obsahom a ich použitie
GB0100624D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
PE20030477A1 (es) * 2001-10-15 2003-06-06 Schering Corp ANTAGONISTAS DEL RECEPTOR DE ADENOSINA A2a
WO2003048165A1 (en) * 2001-11-30 2003-06-12 Schering Corporation ADENOSINE A2a RECEPTOR ANTAGONISTS
US6875772B2 (en) 2001-11-30 2005-04-05 Schering Corporation [1,2,4]-Triazole bicyclic adeonsine A2a receptor antagonists
DE10159922A1 (de) * 2001-12-06 2003-06-26 Gruenenthal Gmbh Substituierte 2-Pyrrolidin-2-yl-1H-indol-Derivate
ES2716404T3 (es) * 2002-01-28 2019-06-12 Kyowa Hakko Kogyo Kk Antagonistas de receptores A2A para su uso en el tratamiento de trastornos del movimiento
JP2006514697A (ja) 2002-12-19 2006-05-11 シェーリング　コーポレイション アデノシンＡ２ａレセプターアンタゴニストの使用
ATE418555T1 (de) 2003-04-09 2009-01-15 Biogen Idec Inc A2a-adenosinrezeptorantagonisten
CN100503609C (zh) 2003-04-23 2009-06-24 先灵公司 2-炔基-及2-链烯基-吡唑并-[4,3-e]-1,2,4-三唑并[1,5-c]-嘧啶腺苷A2a受体拮抗剂
EP1678182B1 (de) * 2003-10-28 2007-02-07 Schering Corporation Verfahren zur herstellung substituierter 5-amino-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
DE602004009962T2 (de) * 2003-12-01 2008-08-28 Schering Corp. Verfahren zur herstellung von substituierten 5-aminopyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidinen
WO2007035542A1 (en) * 2005-09-19 2007-03-29 Schering Corporation 2-HETEROARYL-PYRAZOLO-[4, 3-e]-1, 2, 4-TRIAZOLO-[1,5-c]-PYRIMIDINE AS ADENOSINE A2a RECEPTOR ANTAGONISTS

Also Published As

Publication number Publication date
EP1902716A1 (de) 2008-03-26
EP2258372B1 (de) 2012-05-09
JP2013056911A (ja) 2013-03-28
EP2258372A1 (de) 2010-12-08
EP1902716A4 (de) 2009-05-13
US7851478B2 (en) 2010-12-14
JPWO2006132275A1 (ja) 2009-01-08
WO2006132275A1 (ja) 2006-12-14
JP2015007096A (ja) 2015-01-15
EP2258372B8 (de) 2012-12-19
US20090105277A1 (en) 2009-04-23
ES2385702T3 (es) 2012-07-30

Similar Documents

Publication Publication Date Title
ATE556712T1 (de) A2a antagonisten zur behandlung von motorischen störungen
WO2005018557A3 (en) Substituted pyridinones
AP1822A (en) Substituted pyridinones as modulators of P38 MAP kinase.
PT1159279E (pt) 4-oxo-4,7-di-hidrotieno¬2,3-b|piridino-5-carboxamidas como agentes antivirais
RS20050732A (en) Substituted pyrimidinones
ATE450514T1 (de) Piperazinylalkylpyrazol-derivate zur verwendung als selektive calciumkanalblocker des t-typs und verfahren zu ihrer herstellung
IS8503A (is) Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar
EP1740581A4 (de) Als ?-sekretase-inhibitoren für die behandlung von alzheimer-krankheit geeignete 2,4,6-substituierte pyridylderivatverbindungen
NO20082136L (no) 1,5-substituerte indol-2-yl-amidderivater
EP1757594A4 (de) Chinazolinderivat
CY1112899T1 (el) Παραγωγα θειαδιαζολινης για τη θεραπεια του καρκινου
BRPI0608216A2 (pt) agente terapêutico para um tumor, método para tratar um tumor, e, uso de um composto de benzoìla, uma pró-groga do mesmo ou um sal farmaceuticamente aceitável do mesmo
EA200400466A1 (ru) Производные пиперазина с антагонистической активностью к рецептору ccr1
EP1817311A4 (de) 2,3,4,6-substituierte pyridylderivat-verbindungen als beta-sektretase-inhibitoren zur behandlung von morbus alzheimer
ATE495174T1 (de) 2-oxo-2-(2-phenyl-5,6,7,8-tetrahydroindolizin-3 yl)acetamidderivate und verwandte verbindungen als antipilzmittel
MX2009004314A (es) Diaril, dipiridinil y arilpiridinilderivados y usos de los mismos.
ATE325610T1 (de) Xanthinderivative zur behandlung von hirnischämie
ATE357917T1 (de) Behandlung von dyskinesie durch mu-selektive opioidantagonisten
BRPI0409376A (pt) derivados de indeno como agentes farmacêuticos
WO2006134486A3 (en) Alpha-(aryl-or heteroaryl-methyl)-beta piperidino propanamide compounds as orl1-receptor antagonists
WO2006114666A8 (en) SUBSTITUTED ARYL 1,4-PYRAZlNE DERIVATIVES
WO2004022540A3 (en) Pyridazinone and pyridone derivatives as adenosine antagonists
NO20053805L (no) Diarylmetylindenpiperidinderivater, framgangsmate for fremstilling derav, og anvendelse derav
WO2008136377A1 (ja) 二環式複素環化合物
NO20053997L (no) Oligosaccharidderivat